One of the viable approaches to controlling T2D is via glucagon-like peptide 1 (GLP-1) concerned with the potential of reducing fasting and postprandial glucose in the blood for T2D [3,9,10]. This evidence concerns the gene GCG and type 2 diabetes mellitus.